title: Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.
authors.affiliation: University of Vermont, Burlington, Vermont 05446, USA.
authors.forename: Samer S
authors.initials: SS
authors.lastname: Kabbani
authors.forename: Atul
authors.initials: A
authors.lastname: Aggarwal
authors.forename: Edward F
authors.initials: EF
authors.lastname: Terrien
authors.forename: Peter M
authors.initials: PM
authors.lastname: DiBattiste
authors.forename: Burton E
authors.initials: BE
authors.lastname: Sobel
authors.forename: David J
authors.initials: DJ
authors.lastname: Schneider
mesh_terms: D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D003327:Coronary Disease / Q000097:blood / Q000628:therapy*; D004359:Drug Therapy, Combination; D005340:Fibrinogen / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D005340:Fibrinogen; D006493:Heparin; D000077466:Tirofiban; D000077284:Abciximab